论文部分内容阅读
抗新生血管治疗是实体肿瘤治疗中的有效策略,近年来抗VEGF-A和VEGF-R2受体治疗出现了耐药现象。Notch信号转导是一种细胞间信号通路,在肿瘤新生血管生成中起重要作用。在Notch通路中,Delta样配体4(Delta-like ligand 4, DLL4)在影响肿瘤新生血管生成方面起着重要的作用,它能抑制新生血管分支形成,促进新生血管的成熟;阻断DLL4能增加无功能新生血管数量,加剧恶性肿瘤缺血缺氧,抑制肿瘤的生长。对DLL4蛋白的深入研究为肿瘤新生血管分子靶向治疗提供新的策略和新的靶标,DLL4有可能成为继VEGF后肿瘤血管分子靶向治疗的重要靶点。
Anti-angiogenic therapy is an effective strategy in the treatment of solid tumors. In recent years, the treatment of anti-VEGF-A and VEGF-R2 receptors has emerged as drug resistance. Notch signaling is a cell-cell signaling pathway that plays an important role in tumor angiogenesis. Delta-like ligand 4 (DLL4) plays an important role in affecting tumor angiogenesis in the Notch pathway. It inhibits the formation of new blood vessel branches and promotes the neovascularization. It blocks the activation of DLL4 Increase the number of non-functional neovascularization, aggravating malignant hypoxia, inhibition of tumor growth. The in-depth study of DLL4 protein provides a new strategy and new target for molecular targeted therapy of tumor neovascularization, and DLL4 may be an important target of molecular targeted therapy of tumor angiogenesis after VEGF.